Irinotecan Impurity 18, identified by its CAS number 1255644-71-3, is a chemical compound associated with the anticancer drug irinotecan, which is used primarily in the treatment of colorectal cancer. This impurity is a byproduct that can arise during the synthesis of irinotecan and may affect the drug's efficacy and safety profile. While specific characteristics such as molecular weight, structure, and solubility are not detailed here, impurities like Irinotecan Impurity 18 are typically characterized by their potential to influence the pharmacokinetics and pharmacodynamics of the parent compound. The presence of impurities in pharmaceutical formulations is closely monitored, as they can impact the overall quality, stability, and therapeutic effectiveness of the drug. Regulatory agencies require thorough characterization and quantification of such impurities to ensure patient safety and drug efficacy. Understanding the properties and behavior of impurities is crucial in pharmaceutical development and quality control processes.

Irinotecan Impurity 18

1255644-71-3: Irinotecan Impurity 18, identified by its CAS number 1255644-71-3, is a chemical compound associated with the anticancer drug irinotecan, which is used primarily in the treatment of colorectal cancer. This impurity is a byproduct that can arise during the synthesis of irinotecan and may affect the drug's efficacy and safety profile. While specific characteristics such as molecular weight, structure, and solubility are not detailed here, impurities like Irinotecan Impurity 18 are typically characterized by their potential to influence the pharmacokinetics and pharmacodynamics of the parent compound. The presence of impurities in pharmaceutical formulations is closely monitored, as they can impact the overall quality, stability, and therapeutic effectiveness of the drug. Regulatory agencies require thorough characterization and quantification of such impurities to ensure patient safety and drug efficacy. Understanding the properties and behavior of impurities is crucial in pharmaceutical development and quality control processes.

CAS 1255644-71-3

Irinotecan Impurity 18

(R)-Irinotecan Hydrochloride-d10 Trihydrate

Ref: TR-I767517

(R)-Irinotecan Hydrochloride Trihydrate

Ref: TR-I767505